Singapore, Feburary 2025 – We're excited to announce a major upgrade to the VITAseer software, designed to enhance the analysis of data from the VITA single-cell transcriptome platform. This powerful platform now supports a wider range of applications, including eukaryotic and prokaryotic organisms, along with mRNA, non-coding RNA, and a variety of sample types (fresh, frozen, fixed, and FFPE samples). To better serve evolving research needs, M20 Genomics has restructured VITAseer with three specialized analysis modules: VITAbasic, VITAeuk, and VITAprok. VITAbasic handles preprocessing analysis. VITAeuk and VITAprok provide deeper downstream analysis for eukaryotic and prokaryotic samples, respectively. This update primarily focuses on the enhancements in VITAbasic, designed to improve data processing efficiency and flexibility, addressing the diverse needs of researchers. The updates aim to streamline workflows and provide more insightful results. Structure of VITAseer Key Upgrades: 1. Expanded Microbiome Functional Genome Analysis Module The upgraded VITAbasic now includes a robust module for functional genome analysis of microbiomes. This new feature refines species genome data by eliminating redundancies and constructing a non-redundant functional gene database for comparison. In the analysis of single-cell transcriptomic data from microbiomes, a key improvement is the treatment of homologous genes. Previously, different homologous genes of the same functional gene,…

Singapore, January 2025 – M20 Genomics is proud to announce the successful installation of its cutting-edge VITA Single-Cell Full-Length Transcriptome Platform at the prestigious University Hospital Heidelberg. This milestone marks a new chapter in our European research collaboration, bringing our advanced, high-throughput single-cell sequencing products and technical support to one of the world’s leading academic and medical institutions. Photograph of both teams Empowering Research with Cutting-Edge Single-Cell Technology Following the installation of the VITA platform, M20 Genomics’ technical team conducted comprehensive training for researchers at University Hospital Heidelberg. The sessions covered critical aspects, including experimental workflows, reagent application, and data analysis, ensuring the platform operates at its full potential. The VITA platform at University Hospital Heidelberg will now serve as a central hub for collaborative research in Europe, providing single-cell sequencing services to the hospital and neighboring institutions. Plans are already underway to extend these services to additional clients across the continent. By integrating the VITA platform, University Hospital Heidelberg aims to advance its research on eukaryotic and gut microbiome samples. The laboratory anticipates that this cutting-edge technology will not only strengthen its single-cell sequencing capabilities but also drive significant breakthroughs in medical research and clinical applications, contributing to scientific progress both in…

Singapore, November 2024 - The VITA Single-Cell Transcriptome Platform, developed by M20 Genomics, has been a pioneer in enabling high-throughput, full-length transcriptome sequencing for single-cell research. With its proven capabilities across fresh, frozen, and formalin-fixed paraffin-embedded (FFPE) tissues, VITA Platform consistently meets the needs of researchers across various experimental settings. However, challenges arise in scenarios such as field collections, where immediate processing or freezing of tissue samples may not always be feasible, thus limiting the potential for single-cell sequencing. To overcome these obstacles, we are excited to introduce the VITA Fixed RNA, an RNA fixation reagent (Figure 1), designed for the direct fixation of tissue samples. This new product provides researchers with greater flexibility and broader sample handling options, tailored to accommodate diverse research needs and experimental conditions. By integrating the VITA platform with the VITA Fixed RNA reagent, researchers can confidently navigate the complexities of single-cell transcriptomics, irrespective of sample collection circumstances. Figure 1. VITA Fixed RNA reagent product view Expanding Research Possibilities with VITA Fixed RNA Reagent The VITA Fixed RNA reagent provides a robust method to stabilize tissue samples immediately after collection, preserving the integrity of cellular information until further analysis can be conducted. The following steps…

Singapore, October 2024 - In life sciences research, complex diseases such as cancer, characterized by pronounced spatial heterogeneity within tissues, remain a central focus for spatial transcriptomics applications. Conventional spatial transcriptome platforms, however, typically require fresh-frozen samples and are constrained in their ability to analyze clinical samples like formalin-fixed paraffin embedded (FFPE) tissue. Furthermore, these platforms primarily capture only mRNA, thus omitting the abundant non-coding RNAs present in the transcriptome. Such limitations restrict our capacity to fully understand disease mechanisms. To overcome these technical challenges, in October 2023, we launched M20 Spatial, the world’s first random-priming-based comprehensive spatial transcriptome technology, compatible with all sample types, including FFPE (https://www.m20genomics.com/1085.html ). M20 Spatial captures both mRNA and non-coding RNA, ushering in a new era of multi-species, whole-sample, full-transcriptome, and full-length sequence coverage. Last week, we announced a major upgrade to M20 Spatial, with significant enhancements in sensitivity, resolution, and analytical depth (https://www.m20genomics.com/3818.html). We further evaluate the upgraded M20 Spatial on clinical FFPE tumor samples, confirming its exceptional performance in clinical research and its valuable contributions to understanding tumor heterogeneity. Below, we present the latest data from paired FFPE samples of human breast cancer tissue and peritumoral tissue: High-Sensitivity Detection of Gene Expression…

Singapore, October 2024 - We are thrilled to announce the latest performance upgrade of M20 Genomics' M20 Spatial technology, a revolutionary spatial transcriptomics technology that offers comprehensive spatial transcriptomic data across multiple species and sample types. This upgrade significantly enhances the technology's sensitivity, resolution and data interrogation capabilities, providing researchers a more powerful tool to investigate spatial cell interactions and molecular mechanisms in both research and clinical applications. Unmatched Flexibility in Spatial Transcriptomics Unveiled in October 2023, the M20 Spatial stands as the world’s first technology for whole-sample spatial transcriptomics based on random priming (https://www.m20genomics.com/1085.html). This groundbreaking technology accommodates a wide range of sample types, including fresh, frozen, and formalin-fixed paraffin-embedded (FFPE) tissues. By harnessing random priming, M20 Spatial captures spatial RNA with unbiased full-length transcript coverage, empowering researchers to delve into complete transcriptomes across diverse species and tissue types. M20 Spatial Workflow Compared to traditional spatial transcriptomics technologies, M20 Spatial heralds a new era of innovation, achieving remarkable breakthroughs in applicable species, sample types, RNA capture methods, and comprehensive full-length transcript coverage. These advancements not only elevate the technology’s significance in research and clinical applications but also vastly expand the horizons of information and insights available through spatial transcriptomics…

Last week, we officially launched the Klebsiella Action Project (KAP), a global initiative designed to accelerate research on hypervirulent Klebsiella pneumoniae (hvKp) ST23, a pathogen posing a growing public health threat worldwide. This initiative seeks to gather the global scientific community in a collaborative effort to explore the complex biological characteristics of hvKp ST23, specifically focusing on its resistance mechanisms and virulence factors. However, research on multidrug-resistant hvKp has long been constrained by traditional methods, which fail to offer a comprehensive understanding of resistance mechanisms and the associated functional heterogeneity. The KAP initiative seeks to overcome these limitations by leveraging the VITA single-cell transcriptomics platform, which delivers cutting-edge technology for studying multidrug-resistant hvKp. With its unprecedented resolution, VITA is instrumental in unraveling the complex dynamics of and reshaping the landscape of microbial research. Current Limitations in Research on hvKp Traditional methods such as bulk RNA-sequencing and culture-based techniques are commonly used to investigate microbial communities. However, these techniques present several significant limitations: Low Resolution: Traditional methods generally assess microbial populations at the community level, which overlooks the functional heterogeneity present within individual cells. This approach frequently fails to detect rare but significant events, such as the emergence of antibiotic resistance…

Recently, the World Health Organization (WHO) has sounded the alarm on the escalating global threat posed by hypervirulent Klebsiella pneumoniae (hvKp) sequence type (ST) 23, a pathogen now recognized as a serious public health threat due to its rapid spread and high mortality rates. In direct response, M20 Genomics is launching the Klebsiella Action Project (KAP), dedicated to accelerating research and innovation to combat this deadly bacterium. The Urgent Threat of hvKp ST23 Klebsiella pneumoniae is a typically harmless gram-negative bacterium residing human mucosal surfaces of the oropharynx and gastrointestinal (GI) tract. However, the emergence of the hypervirulent hvKp ST23 strain has transformed this microbe into a formidable pathogen capable of causing severe, life-threatening infections in even healthy individuals, including pneumonia, bloodstream infections, and meningitis. On July 31, 2024, the WHO report highlighted the global spread of hvKp ST23 carrying resistant genes to the carbapenem antibiotics across six WHO Regions. Countries including United States, United Kingdom, China, and France all have reported the existence of hvKp ST23. The strain's resistance to carbapenems, a last-line antibiotic, coupled with its rapid dissemination, particularly within healthcare settings, underscores its potential to trigger widespread outbreaks. The Rising Clinical Challenge Caused by hvKp The clinical…

Baltimore, MD, USA, August 2024 – M20 Genomics, a pioneer in cutting-edge single-cell and spatial transcriptomics, and Complete Omics, a leader in clinical proteomics and metabolomics, have joined forces in a strategic collaboration to drive innovations in single-cell multi-omics. This partnership aims to integrate cutting-edge technologies from both companies to revolutionize disease research and precision medicine. This collaboration unites M20 Genomics' innovative single-cell and spatial transcriptomics platforms with Complete Omics' leading proteomics and metabolomics technologies. By combining these powerful tools, the partnership will enable comprehensive multi-omics analysis at the single-cell level, providing researchers with unprecedented insights into cellular heterogeneity, tissue architecture, and disease mechanisms. This integration is expected to enhance the precision and application of multi-omics technologies in disease research and personalized medicine. Establishment of Joint Laboratory A key aspect of this collaboration is setting up a joint laboratory in Baltimore, Maryland, close to Johns Hopkins University. This lab will serve as a hub for developing and optimizing integrated single-cell multi-omics assays, merging M20 Genomics' single-cell and spatial transcriptomics expertise with Complete Omics' proteomics and metabolomics technologies. Both companies aim to create powerful tools for multi-omics research, enabling detailed mapping of gene, protein, and metabolite expression at the single-cell level.…

We are excited to announce a significant update to our VITAseer software, now featuring an advanced module designed for in-depth single-cell analysis of eukaryotic samples. This upgrade also introduces comprehensive single-cell lncRNA (long non-coding RNA) analysis capabilities, further enhancing the power and precision of research. The upgraded VITAseer is fully compatible with the extensive single-cell transcriptome data generated by VITA single-cell products, providing a more intuitive and efficient data analysis experience. Key enhancements include improved cell clustering, automated cell type annotation, functional analysis, and cell communication mapping. In addition, this latest version of VITAseer offers single-cell lncRNA analysis. LncRNAs, non-coding RNA molecules longer than 200 nucleotides, exert major influence on a diverse array of molecular mechanisms, including epigenetics, transcription factor regulation, and post-transcriptional processes. As integral components of complex molecular networks, lncRNAs are increasingly recognized as key players in a wide range of diseases. To deepen the understanding of lncRNA functions, we have introduced a first-of-its-kind analysis module specifically designed for single-cell mRNA and lncRNA analysis of eukaryotic samples. New Features of Upgraded VITAseer: 1. UMAP Visualization of Cell Clusters Using Both mRNAs and LncRNAs The upgraded VITAseer introduces a new UMAP visualization feature, allowing users to analyze cell clusters…

Los Angeles, CA – M20 Genomics is pleased to announce the installation of its VITA Single-Cell Full-Length Transcriptome Platform at the Genomics and Bioinformatics Technology Center (TCGB) at the University of California, Los Angeles (UCLA). This collaboration significantly enhances the spectrum of tools available to local research teams, enabling transcriptomic profiling in various sample types and species with single-cell resolution.   VITA platform at the TCGB at the UCLA.   Revolutionizing Transcriptome Analysis with VITA at TCGB Utilizing M20 Genomics‘ innovative random primer-based M20 Seq technology, the VITA platform provides unparalleled sample coverage. It accommodates a wide range of sample types, including fresh, frozen, and FFPE samples. Its unique capabilities extend to a diverse array of biological species, from eukaryotes to bacteria, and it is particularly designed for processing complex microbial samples such as gut microbiota. This paves the way for novel insights in various research fields, from cancer research to microbiology. With the installation of the VITA Platform our technical experts have delivered extensive, in-depth training to the TCGB team. Covering every critical aspect of the workflow—from sample preparation to advanced data analysis—this extensive training ensures that the TCGB team is exceptionally equipped to leverage the full potential of…

ASM Microbe 2024, held from June 13 to 17 in Atlanta, once again proved to be a cornerstone of the microbiology community, drawing together attendees from all fields of microbiology, eager to explore groundbreaking insights, pioneering technologies, and new collaborations and partnerships. The atmosphere at ASM Microbe 2024 was one of inspiration and innovation. Our team was honoured to present our cutting-edge VITA platform for single-cell transcriptome profiling in microbial samples to the global microbiology community. We engaged with numerous dedicated professionals, forging exciting collaborations that promise to shape the future of microbial research.   Our booth emerged as a hub of innovation, drawing in microbiologists eager to learn and explore the advanced capabilities of the VITA platform. Interactive demonstrations allowed visitors to experience the ease and efficiency of the VITA platform firsthand. Personal consultations provided attendees with tailored insights on how the VITA platform could enhance their research projects. M20 Genomics’ booth at ASM Microbe 2024 Pioneering Insights into the Microbial Universe with VITA The highlight of M20 Genomics’ participation was our Industry and Science Showcase, where our Vice President of Academic Affairs and Innovation, Dr. Qing Yan, highlighted VITA's outstanding capabilities in detail. Dr. Qing Yan, Vice President of…

M20 Genomics is thrilled to showcase its revolutionary single-cell RNA sequencing technologies at booth 1537 during ASM Microbe 2024. As pioneers in single-cell technologies, we're thrilled to showcase our latest innovations at this highly anticipated event, taking place from June 13 to 17, 2024, at the Georgia World Congress Center in Atlanta. With thousands of scientists, researchers, and healthcare professionals converging at ASM Microbe, this event promises unparalleled opportunities to exchange groundbreaking ideas, engage with global leaders, and forge transformative connections within the scientific community. At M20 Genomics, we're excited to showcase our groundbreaking solutions revolutionizing microbiology by enabling the precise analysis of the complex heterogeneity within the microbial universe.      Highlights of M20 Genomics' Participation at ASM Microbe 2024: 1. Innovative Products: M20 Genomics is poised to present its groundbreaking VITA high-throughput single-cell transcriptome platform. This revolutionary technology enables comprehensive transcriptome profiling at the single-bacterialevel, providing unparalleled insights for the precise investigaton of functional and phenotypic heterogeneity across cultured bacteria and gut microbiota.   2. Industry and Science Showcase: Engage with M20 Genomics' expert during our informative Industry and Science Showcase on June 16 at 11:00 AM in Theater A at the Georgia World Congress Center. M20 Genomics will present compelling data and application…

Durham, NC – M20 Genomics is pleased to announce the installation of its VITA Single-Cell Full-Length Transcriptome Platform in our collaboration labs at Duke University School of Medicine, significantly enhancing the research tools available to local teams. This strategic partnership with our esteemed collaborating research groups substantially advances the scientific resources at Duke University School of Medicine, enabling precise transcriptomic profiling at the single-cell level and providing detailed insights into cellular mechanisms.     Fully operational VITA platform in on of our collaboration labs at Duke University School of Medicine.   Unlocking New Frontiers in Single-Cell Analysis with Enhanced Capabilities Following the successful deployment of the VITA platform, our technical team has provided comprehensive training for Duke researchers. This training encompassed experimental protocols, instrument and reagent usage, and proficiency in data analysis software, ensuring optimal utilization of the platform's advanced capabilities. The integration of the VITA platform further strengthens the research infrastructure at Duke University School of Medicine, facilitating single-cell transcriptomic profiling across diverse sample types.   Duke researcher conducting single-cell RNA sequencing with VITA platform.   Utilizing innovative random primer-based M20 Seq technology, the VITA platform offers unparalleled sample coverage. It accommodates a wide range of sample types, including fresh, frozen,…

In March 2022, we proudly unveiled our innovative high-throughput single-bacterium RNA sequencing technology, MscRNA Seq (incooperated in M20 Seq) alongside the VITApilote High-Throughput Single-Bacterium Transcriptome Kit. Our groundbreaking advancement sparked a transformative shift in microbiological research towards single-bacterium transcriptomics. As scientific exploration in microbiology ventures into unknown territories with increased complexity and precision, particularly within the intricate realm of gut microbiota, we have committed to confronting emerging challenges and facilitating a deeper understanding of this vital microbial community. We are thrilled to present the latest addition to our VITA single-cell transcriptome product family - VITA GutMicrobiome (Figure 1). This product stands as the world's first high-throughput single-bacterium transcriptomic solution designed for gut microbiome studies, empowering researchers to gain comprehensive insights into the intricate world of gut microbiota. Figure 1. VITA GutMicrobiome product The introduction of VITA GutMicrobiome marks the addition of a powerful tool available to researchers studying the functionality of gut microbiota. By expanding the scope of analysis to the single-cell level, this breakthrough holds the potential to significantly advance comprehensive investigations in various fields, including gut microbiota functions, live biotherapeutic products, fecal microbiota transplantation, microbiota-drug interactions, and beyond.   The Current Status of Gut Microbiota Research The gut…

In August 2022, we proudly introduced M20 Seq®, our revolutionary single-cell sequencing technology based on random primers, setting a new standard in comprehensive transcriptome analysis. Accompanying this innovation was the launch of our VITA Single-Cell Full-Length Transcriptome Sequencing Platform, enabling the comprehensive exploration of whole transcriptomes across diverse sample types and species. Our dedication to scientific progress extends beyond existing technologies. Acknowledging the intricate multidimensional complexities of biological mechanisms, which span both the temporal and spatial scale, we are inspired to foster novel and comprehensive insights into their complex organization and regulation. This commitment fuels our continuous efforts to deliver innovative approaches that push the boundaries of current technologies, paving the way for pioneering discoveries that will shape the future of biomedicine. We are thrilled to present a groundbreaking advancement: 'M20 Spatial' – our revolutionary spatial whole transcriptome solution, powered by our random-primer technology. M20 Spatial marks a groundbreaking shift in spatial transcriptomics, expanding species applicability and sample type compatability, improving RNA capture efficiency, and enhancing sequence coverage. With M20 Spatial, we empower the scientific community to delve deeper into the spatial and temporal dimensions of cellular processes, driving advancements and leading discoveries at the forefront of biomedical research. Embrace…

In August 2022, M20 Genomics officially launched M20 Seq a groundbreaking single-cell sequencing technology based on random primers. The introduction of this cutting-edge technology signifies the onset of a new era in single-cell sequencing, extending beyond scientific research towards the prospect of future clinical applications. Leveraging the M20 Seq technology, M20 Genomics has simultaneously introduced the VITA series - a revolutionary high-throughput single-cell sequencing product line. With the capability for (ultra) high-throughput transcriptome sequencing across an extensive spectrum of samples, species, and full-length transcriptome capture, VITA significantly enhances detection sensitivity and broadly expands the application scope of single-cell technology.   A Glimpse into the Current Possibilities and Challenges of Single-Cell Technology With its capacity to dissect cellular heterogeneity within complex tissues, single-cell sequencing has surpassed the constraints of traditional bulk transcriptome sequencing. Widely adopted for cellular atlas construction, it is also gaining prominence in clinical research. Furthermore, its potential spans early disease detection, monitoring, and personalized medicine in fields like oncology, immunology, and neuroscience. Despite achieving technological breakthroughs in high-throughput and multi-omics approaches, challenges persist for single-cell sequencing technology. Issues such as low sensitivity and high costs pose critical barriers to the advancement of single-cell-related research. While most high-throughput single-cell…

In March 2022, M20 Genomics proudly launched MscRNA-seq (Microbial-single-cell RNA sequencing). This pioneering platform marks a significant leap as single-cell transcriptome sequencing technology enters the commercial stage within the field of microbial research. The availability of MscRNA-seq facilitates the transcendence of current technological constraints, enabling the comprehensive study of bacterial drug resistance and persistence mechanisms, pathogenicity, and intricate bacterial-host interactions.   The Current State of Single-Cell Sequencing Technology Single-cell sequencing technology has emerged as a powerful tool for detecting gene expression and other information at the level of individual cells. This innovation addresses a critical limitation in traditional research methodologies, where sequencing bulked samples from tissues or cell populations can mask the transcriptional heterogeneity between individual cells by averaging across a population. Antimicrobial resistance (AMR) is emerging as one of the major public health problems of this century. In its 2014 Global Antimicrobial Resistance Report, the World Health Organization (WHO) disclosed that drug-resistant bacterial infections claimed over 700,000 lives globally within a single year. Predictive models suggest a worrisome scenario, projecting that by 2050, fatalities from antibiotic resistant bacterial infections could exceed 10 million per year, surpassing even the projected 8.2 million cancer-related deaths for the same period. The heterogeneity…